» Articles » PMID: 36503486

The Correlation Between Triiodothyronine and the Severity of Liver Fibrosis

Overview
Publisher Biomed Central
Specialty Endocrinology
Date 2022 Dec 12
PMID 36503486
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The severity of liver fibrosis is an important predictor of death in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). However, there is still no definite conclusion on the relationship between triiodothyronine (T3) and the severity of liver fibrosis. Thus, the aim of this study was to analyze the correlation between T3 level and the severity of liver fibrosis.

Methods: We performed a cross-sectional study of 2072 T2DM patients with normal thyroid function from January 2017 to January 2020. NAFLD fibrosis score (NFS), Fibrosis index based on the 4 factors (FIB-4) and BARD score (BARD) were used to assess the severity of fibrosis in T2DM patients, and linear regression analyses were used to determine the factors independently associated with liver fibrosis. Further experiments were performed to assess the impact of low T3 on fibrosis progression in mice model and explore possible mechanisms.

Results: Free triiodothyronine (fT3) levels had significantly inverse correlations with NFS and FIB-4, and BARD in T2DM patients (P < 0.05). In multiple linear regression analyses, decreased fT3 level was an independent risk factor for the severity of liver fibrosis of T2DM patients (P < 0.01). Findings from in-vivo experiment using mice model proved that hypothyroidism mice had more severe of liver fibrosis than those mice with normal thyroid function. We also found that T3 could inhibit the profibrotic TREM2CD9 macrophage, which had been identified an important player in the progression of liver fibrosis.

Conclusion: The findings from this study proved an inverse correlation between T3 level and the severity of liver fibrosis, and lower fT3 level within the normal range was an independent risk factor for severe liver fibrosis.

Citing Articles

Role of triggering receptor expressed on myeloid cells 2 in the pathogenesis of non-alcoholic fatty liver disease.

Zhang L, Liu S, Zhao Q, Liu X, Liu T, Zhang Q World J Hepatol. 2025; 17(2):102328.

PMID: 40027566 PMC: 11866134. DOI: 10.4254/wjh.v17.i2.102328.


Research Advancements in the Interplay between T3 and Macrophages.

Yang L, Fu M, Wang H, Sun H Curr Med Sci. 2024; 44(5):883-889.

PMID: 39446284 DOI: 10.1007/s11596-024-2935-6.


Epigenetic regulation of thyroid hormone action in human metabolic dysfunction-associated steatohepatitis.

Naujack A, Krause C, Britsemmer J, Taege N, Mittag J, Kirchner H Eur Thyroid J. 2024; 13(5).

PMID: 39312733 PMC: 11466269. DOI: 10.1530/ETJ-24-0080.


Correlation Between Thyroid-Stimulating Hormone (TSH) and Liver Function Test Values in North Karnataka Patients Admitted to a Tertiary Care Hospital.

Murali Krishna S, Hegde S, Chellathurai M, Mohandas N, Guruswamy S, Pandit S Cureus. 2024; 16(4):e59004.

PMID: 38803746 PMC: 11128325. DOI: 10.7759/cureus.59004.


The Free Triiodothyronine, Gamma-Glutamyl Transpeptidase and Spontaneous Bacterial Peritonitis Index: A Novel Model for Predicting 1-Year Mortality in Patients with HBV-Related Hepatic Encephalopathy.

Lin L, Huang Z, Liu K, Tong X, Zhang Z, Xue Y Hepat Med. 2024; 16:1-9.

PMID: 38283915 PMC: 10819082. DOI: 10.2147/HMER.S450638.

References
1.
Sun W, Cui H, Li N, Wei Y, Lai S, Yang Y . Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study. Hepatol Res. 2016; 46(9):862-70. DOI: 10.1111/hepr.12647. View

2.
Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

3.
Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y . Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2011; 130(7):1639-48. DOI: 10.1002/ijc.26165. View

4.
Harrison S, Bashir M, Guy C, Zhou R, Moylan C, Frias J . Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019; 394(10213):2012-2024. DOI: 10.1016/S0140-6736(19)32517-6. View

5.
Salvatore D, Porcelli T, Ettleson M, Bianco A . The relevance of T in the management of hypothyroidism. Lancet Diabetes Endocrinol. 2022; 10(5):366-372. PMC: 9987447. DOI: 10.1016/S2213-8587(22)00004-3. View